Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virology

Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients

Xiaodong Li, Lin Wang, Yanwei Zhong, Vincent Wai-Sun Wong, Zhihui Xu, Yan Liu, Qinghong Li, Shaojie Xin, Jingmin Zhao, Dongping Xu
Xiaodong Li
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Wang
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanwei Zhong
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Wai-Sun Wong
2Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhihui Xu
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Liu
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qinghong Li
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaojie Xin
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingmin Zhao
3Department of Pathology, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xudongping@yahoo.com jmzhao302@163.com
Dongping Xu
1Viral Hepatitis Research Laboratory, Institute of Infectious Diseases and Liver Failure Research Center, Beijing 302 Hospital, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xudongping@yahoo.com jmzhao302@163.com
DOI: 10.1128/JCM.01518-10
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We aimed to study the prevalence and clinical implications of hepatitis B virus (HBV) subgenotypes in Chinese patients. A total of 4,300 patients, mainly from northern China, were enrolled, including 182 patients with acute hepatitis B and 4,118 patients with chronic HBV infection who had been exposed to nucleoside or nucleotide analogs. HBV genotypes/subgenotypes were determined by direct sequencing of the HBV S/Pol region. The prevalence rates were 0.40% for HBV/B1, 14.30% for HBV/B2, 0.25% for HBV/B3, 0.35% for HBV/B4, 1.05% for HBV/C1, 81.72% for HBV/C2, 0.93% for HBV/C3, 0.16% for HBV/C4, and 0.84% for HBV/D. In chronic HBV infection, patients with HBV/B2 were younger and had lower ΗBeAg positive rates than patients with HBV/C2. The incidence of lamivudine-resistant mutations was significantly higher in HBV/C2 compared to HBV/B2 (27.9% versus 19.8%; P < 0.01), and the significant difference was observed only for rtM204I and not rtM204V. In addition, compensatory mutations were more frequently detected in HBV/C2. The incidence of adefovir-resistant mutations was similar between the two subsets, but HBV/C2 inclined to show rtA181V (3.6% for C2 versus 0.9% for B2; P < 0.01), while HBV/B2 inclined to show rtN236T (4.5% for versus 2.5% for C2; P < 0.01). The ratios of HBV/B2 to HBV/C2 infection were 1.7 (110/65), 5.7 (2,653/463), 7.5 (520/69), 8.0 (48/6), and 15.3 (183/12) for acute hepatitis B, chronic hepatitis B, liver cirrhosis, acute-on-chronic liver failure, and hepatocellular carcinoma, respectively. In conclusion, HBV/C2 and HBV/B2, two prevalent subgenotypes, differ in lamivudine- and adefovir-resistance-associated mutational patterns. HBV/C2-infected patients are more likely to have disease progression than HBV/B2-infected ones.

Hepatitis B virus (HBV) infection remains a serious health problem that currently affects about 350 million people worldwide and 93 million in China (12, 20). HBV infection is associated with a wide spectrum of clinical presentations, including asymptomatic subclinical infection, acute hepatitis B (AHB), chronic hepatitis (CHB), liver cirrhosis (LC), acute-on-chronic liver failure (ACLF), and hepatocellular carcinoma (HCC). Factors associated with disease progression remain largely unknown. Viral factors have been implicated in the pathogenesis and clinic outcome of HBV infection (23).

HBV exhibits a mutation rate of around 2 × 104 base substitutions/site/year, which is an approximately 100 times higher than that of other DNA viruses (5). HBV is at least classified into eight genotypes, based on nucleotide sequence divergence among strains of >8%. In Asia, HBV genotypes B and C are the predominant genotypes, and HBV genotype C is associated with more severe liver disease, delayed HBeAg seroconversion, and a high risk of HCC (7, 8, 10, 17, 18, 24). Within each HBV genotype, subgenotypes have been identified based on a 4 to 8% difference in the complete nucleotide sequence. HBV/B, HBV/C, and HBV/D have been individually classified into five subgenotypes each, namely, HBV/B1 through HBV/B5, HBV/C1 through HBV/C5, and HBV/D1 through HBV/D5 (22). In China, the majority of genotype B HBV isolates belongs to subgenotype B2, while C1 and C2 were predominant subgenotypes in northern and southern parts of China, respectively (30, 31, 32). HBV subgenotypes may have differences in terms of prevalence of HBeAg and HCC development (25, 39, 40). Patients infected by HBV/C1 were reported to have more severe clinical features than those infected by HBV/C2 (42). A Chinese study showed that HBV/C2 infection was more prone to cause chronic infection than HBV/B2 infection (41). However, the clinical implications of HBV subgenotypes remain controversial; e.g., there was a report showing no correlation between HBV/C subgenotypes and disease progression (29).

Nucleoside and nucleotide analogs (NA) are commonly used clinically for suppressing viral replication to halt the progression of liver diseases caused by chronic HBV infection. However, viral resistance is the main drawback of long-term antiviral therapy. To date, data on the association of HBV subgenotype with drug resistance are very limited and uncertain. A study in Germany suggested that the rate of resistance to lamivudine (LAM) was higher in patients with HBV genotype A infection than in patients with genotype D infection (43), an Indian study of 76 patients reported that genotype D is more likely than genotype A to have a sustained virologic response after LAM therapy (28), and an Italian study on 27 patients showed that biochemical and virological responses to LAM do not vary between genotypes A and D (4). Two investigations from southeast Asian regions suggested that patients infected with HBV genotype C had a poorer virologic response to LAM treatment and a higher rate of posttreatment relapse than patients infected with genotype B (9, 16), but another investigation from the United States suggested that patients infected with HBV genotype B appear to have earlier biochemical resistance to LAM than those infected with HBV genotype C (15). In most of the studies, the sample size was relatively small, and this may bring uncertainty to the results. There is still a paucity of data presenting the association of HBV genotypes/subgenotypes with viral resistance to adefovir (ADV) and entecavir (ETV).

In this study, we aimed to investigate the prevalence and clinical implications of HBV subgenotypes in a large cohort of Chinese patients with HBV infection.

MATERIALS AND METHODS

Patients.A total of 4,300 patients with AHB (n = 182), CHB (n = 3,247), LC (n = 613), ACLF (n = 55), or HCC (n = 203) who visited Beijing 302 Hospital from July 2007 to June 2009 were enrolled in the study. Patients were mainly from different regions of northern China. The diagnostic criteria were based on the Management Scheme of Diagnostic and Therapy Criteria of Viral Hepatitis and on the Diagnostic and Treatment Guidelines for Liver Failure, which were issued by the Chinese Society of Infectious Diseases and Parasitology and by the Chinese Society of Hepatology and have been described in detail in our previous studies (14, 21, 24, 34, 44). All patients were positive for HBV DNA (≥100 IU/ml or 500 copies/ml) at sampling. All subjects except AHB patients were exposed to different regimens of nucleoside/nucleotide analogs. The study was approved by the Ethics Committee of Beijing 302 Hospital.

Serological markers and quantitation of HBV DNA.Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), prothrombin activity (PTA), and other biochemical parameters were measured by standard procedures. HBeAg/anti-HBe, HBsAg/anti-HBs, and anti-HBc were detected by enzyme-linked immunosorbent assay (Kewei Diagnostic Ltd., Beijing, China) or chemiluminescent assay (Abbott Laboratories, Chicago, IL). The HBV DNA level was determined with a real-time PCR kit (Fosun Pharmaceutical Co., Shanghai, China) with a lower limit of detection of 100 IU/ml.

HBV genotype/subgenotype classification.HBV genotype/subgenotype assignment was based on phylogenetic analysis of the 1,225-bp-long S/Pol gene sequence (nucleotides [nt] 54 to 1278) as described previously (21). The sense and antisense primers for the first-round PCR were 5′-AGTCAGGAAGACAGCCTACTCC-3′ (nt 3146 to 3167) and 5′-AGGTGAAGCGAAGTGCACAC-3′ (nt 1577 to 1596), respectively. The sense and antisense primers for second-round PCR were 5′-TTCCTGCTGGTGGCTCCAGTTC-3′ (nt 54 to 75) and 5′-TTCCGCAGTATGGATCGGCAG-3′ (nt 1258 to 1278), respectively. Direct sequencing was performed using an ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA). Phylogenetic and molecular evolutionary analyses were performed in MEGA version 4 (25a). Phylogenetic trees were constructed using neighbor-joining (NJ) analysis with bootstrap test confirmation performed on 1,000 resampling standard reference sequences acquired from the online Hepatitis Virus Database (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi ).

Analysis of genotypic drug resistance.Drug-resistance-associated mutations in the reverse transcriptase (RT) region of the HBV genome were analyzed as previously described (38). Substitutions at positions rt80, rt173, rt180, rt181, rt184, rt202, rt204, rt236, and rt250 were taken as resistance-associated mutations for analysis.

Statistical analysis.Continuous variables were expressed as means ± standard deviations or medians. Differences in continuous data were examined by Student's t test, analysis of variance, or the nonparametric Wilcoxon signed-rank test where appropriate, while differences in categorical data were examined by the chi-square test or Fisher's exact test. Logistic regression was used to evaluate P values in multivariate analysis. Statistical analysis was carried out with SPSS 16.0 software. A P value of <0.05 was considered statistically significant.

RESULTS

Classification of HBV genotypes/subgenotypes.Among a total of 4,300 patients, the subgenotype distribution was as follows: 17 (0.40%) for B1, 615 (14.30%) for B2, 11 (0.25%) for B3, 15 (0.35%) for B4, 45 (1.05%) for C1, 3,514 (81.72%) for C2, 40 (0.93%) for C3, 7 (0.16%) for C4, and 36 (0.84%) for genotype D. Within genotype D, 20 samples were D1, 3 were D2, 4 were D3, 7 were D4, and 2 failed to be classified into subgenotypes. No other genotypes (A, E, F, G, or H) were detected in the patients enrolled in this study. Thus, HBV/C2 was the most predominant subgenotype, followed by HBV/B2 in northern China. A phylogenetic tree based on the 38 representative analyzed HBV genetic sequences with GenBank accession numbers is presented in Fig. 1.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Neighbor-joining phylogenetic tree based on the 38 representative analyzed HBV genetic sequences with GenBank accession numbers. Standard reference sequences are marked by circles.

HBV subgenotypes in relation to clinical features.In patients with AHB, no obvious differences in age, gender, HBV DNA level, TBIL, PTA, ALT, AST, or HBeAg-positive rate were observed between HBV/C2- and HBV/B2-infected patients (Table 1). In patients with chronic HBV infection, however, those with HBV/B2 were younger and had lower HBeAg-positive rates than patients with HBV/C2. There was no significant difference between the two subsets in the other observed parameters (Table 2).

View this table:
  • View inline
  • View popup
TABLE 1.

HBV subgenotypes in relation to clinical features in patients with acute hepatitis B (n = 182)

View this table:
  • View inline
  • View popup
TABLE 2.

HBV subgenotypes in relation to clinical features in patients with chronic HBV infection (n = 4,118)

Comparison of drug-resistant mutational patterns between HBV/B2 and HBV/C2.There was no significant difference between HBV-B2- and HBV/C2-infected patients in the proportion and duration of treatment with individual NAs (Table 3). Comparison of drug-resistant mutational patterns between HBV/B2- and HBV/C2-infected patients showed that the two subsets had differences in LAM- and ADV-resistant mutational patterns. With respect to LAM-resistance-associated mutations, HBV/C2-infected patients had a significantly higher incidence of total primary resistance mutations (sum of rtM204I, rtM204V, and rtM204I/V), rtM204I, and compensatory mutations rtL80I, rtV173L, and rtL180M. In addition, concomitance of rtM204I with the compensatory mutation(s) (with any of L80I, V173L, and L180M) was more frequently detected in HBV/C2- than in HBV/B2-infected patients. The proportion of the concomitant mutation(s) in total M204I-positive samples was 43.6% for HBV/B2 and 67.2% for HBV/C2 (P < 0.01) (Table 4). The incidences of adefovir-resistant mutations were similar in the two subsets. However, HBV/C2-infected patients had a higher rtA181V incidence but a lower rtN236T incidence than HBV/B2-infected patients. No obvious difference in occurrence of ETV-resistant mutations was observed between HBV/C2- and HBV/B2-infected patients (Table 5).

View this table:
  • View inline
  • View popup
TABLE 3.

Comparison of nucleoside/nucleotide analog administration between HBV/B2- and HBV/C2-infected patientsa

View this table:
  • View inline
  • View popup
TABLE 4.

Comparison of incidences of lamivudine-resistance-associated mutations between patients chronically infected with HBV/B2 (n = 550) and HBV/C2 (n = 3,404)

View this table:
  • View inline
  • View popup
TABLE 5.

Comparison of incidences of adefovir and entecavir resistance mutations between patients chronically infected with HBV/B2 (n = 550) and HBV/C2 (n = 3,404)

HBV subgenotypes in relation to disease category.Table 6 summarizes the HBV subgenotypes in relation to the different disease categories. The ratios of HBV/B2 to HBV/C2 infection were 1.7 (110/65), 5.7 (2,653/463), 7.5 (520/69), 8.0 (48/6), and 15.3 (183/12) for AHB, CHB, LC, ACLF, and HCC, respectively.

View this table:
  • View inline
  • View popup
TABLE 6.

HBV subgenotypes in relation to disease progression

DISCUSSION

Previous studies have shown that that HBV genotype C predominates in northern China, genotype B predominates in southern China, genotype D is prevalent in Xinjiang, genotype A is rare, and genotypes E, F, G, and H are not found in China. Recently, investigations of HBV subgenotypes have attracted much attention. A study of 211 Chinese patients in Guangdong Province in southern China showed that HBV subgenotypes B2, C1, and C2 were the most prevalent HBV variants and that the three subgenotypes had different mutational incidences in the basal core promoter (BCP) and precore regions (33). Another study investigated 304 HBV-infected patients and showed that C2 is the most prevalent subgenotype in northeast China (30). However, the clinical implications of HBV subgenotype are far from well understood. Further studies are needed to provide knowledge about HBV genotypes/subgenotypes with respect to viral latency, HBeAg seroconversion, pathogenesis of liver disease, immune escape, treatment response, and resistance to antiviral drug therapy.

In this study, we systematically analyzed the association between disease categories and HBV subgenotypes. Interestingly, the ratio of HBV subgenotypes C2 and B2 rose in the order of CHB, LC, ACLF, and HCC. In addition, HBV/C2-infected patients were older and had a higher HBeAg-positive rate than HBV/B2-infected patients. These results suggested that HBV/C2 is associated with disease progression, whereas HBV/B2 is associated with resolution. It is suggested that HBV/B2 infection is more likely to induce optimal immune responses than HBV/C2 infection due to intrinsic virologic features. Consistent with previous studies (30, 33), we found that HBV/B2 had a significantly lower incidence of BCP mutations A1762T/G1764A but a higher incidence of precore mutation G1896A than HBV/C2 (data not shown). As BCP and precore mutations may influence HBV replication and/or HBeAg expression, whether the BCP/PC mutations may account for the different outcomes for patients with HBV/B2 and HBV/C2 warrants further clarification.

Currently, PCR-restriction fragment length polymorphism (RFLP) and direct PCR sequencing are the most popular methods for HBV subgenotyping. Although direct PCR sequencing is more time-consuming, it may offer abundant information and is taken as a “gold standard.” However, the sensitivity of direct PCR sequencing is usually lower, and it may not detect samples with a low viral load, which is often the case. We developed a highly sensitive nested PCR assay allowing us to analyze samples with quite low viral loads (≥20 IU/ml), as we had done in a study of severe acute respiratory syndrome (SARS) coronavirus (35, 36, 37). The 1,225-bp-long S/Pol gene fragment amplified in our study encompasses the complete S gene and partial PreS and Pol gene fragments for phylogenetic tree analysis of HBV subgenotypes. Similar methods have been used by other investigators (11, 13, 22). To verify the results, we sequenced 113 complete HBV genomes from enrolled samples (GenBank accession numbers FJ386574 through FJ386689, except FJ386599, FJ386646, and FJ386647) and compared the classification of subgenotypes determined on the basis of S/Pol gene fragments with those determined on the basis of complete HBV genomes. The results showed a 99.1% (112/113) concordance between the two assays. Only one sequence assigned to HBV/C1 based on the 1,225-bp fragment was classified as HBV/C2 based on the complete HBV genome (FJ386664). It was verified to be a recombinant strain because it was classified as HBV/C2 based on the precore/core region. As the 1,225-bp amplicon encompasses the complete reverse transcriptase (RT) region of the HBV polymerase gene, all well-recognized drug resistance mutations could be analyzed simultaneously.

rtM204I and rtM204V are classical LAM resistance mutations and often coexist with compensatory mutations (rtL80I, rtV173L, and rtL180M) (1). rtN236T and rtA181V are two well-recognized ADV resistance mutations (2, 3). Substitutions in rtT184, rtS202, or rtM250 in conjunction with LAM resistance mutations result in ETV resistance (26, 27). Unlike in a rigorously designed clinical trial, the patients with chronic HBV infection enrolled in this study were from routine clinical practice with different treatment regimens and durations. The duration of treatment may influence the incidence of resistant HBV strains, although the influence was relatively minor in the large-population samples of our study. Nevertheless, HBV/B2 and HBV/C2 exhibited different LAM- and ADV-resistant mutational patterns, suggesting that HBV subgenotypes might have an impact on drug resistance. To our knowledge, an association of ADV resistance with HBV subgenotypes B2 and C2 has not been documented so far. Compared to rtA181V, rtN236T confers a greater reduction of ADV sensitivity in vitro (3). On the other hand, rtL80I is reported to be associated with a poor response to ADV (19), and the coselection of rtL180M in patients with rtM204I decreased serum ALT normalization significantly after ADV therapy (6). Further study is required to clarify the impact of the difference in drug-resistant mutational patterns on the antiviral response to ADV treatment in clinical practice.

In conclusion, the present study verifies that HBV/C2 is the most predominant subgenotype, followed by HBV/B2 in northern China. HBV/C2 and HBV/B2 differ in LAM- and ADV-resistance-associated mutational patterns, and HBV/C2-infected patients are more likely to have disease progression than HBV/B2-infected ones. Our results provide new insight into features of HBV subgenotypes which may have important clinical implications for management of HBV infection in China.

ACKNOWLEDGMENTS

This work was supported by the Beijing Natural Science Foundation (7091006), the National Key Basic Research Developing Project (2007CB512803), and the National 11th Five-Year Special Grand Project for Infectious Diseases (2008ZX10002-005-6, 2008ZX10002-011, and 2009ZX10004-314).

FOOTNOTES

    • Received 28 July 2010.
    • Returned for modification 1 September 2010.
    • Accepted 16 September 2010.
  • Copyright © 2010 American Society for Microbiology

REFERENCES

  1. 1.↵
    Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 : 1670-1677.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 : 292-297.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Borroto-Esoda, K., M. D. Miller, and S. Arterburn. 2007. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J. Hepatol. 47 : 492-498.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Buti, M., M. Cotrina, A. Valdes, R. Jardi, F. Rodriguez-Frias, and R. Esteban. 2002. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J. Hepatol. 36 : 445-446.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Buti, M., F. Rodriguez-Frias, R. Jardi, and R. Esteban. 2005. Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypes. J. Clin. Virol. 34(Suppl. 1): S79-S82.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Cha, C. K., H. C. Kwon, J. Y. Cheong, S. W. Cho, S. P. Hong, S. O. Kim, and W. D. Yoo. 2009. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J. Med. Virol. 81 : 417-424.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Chan, H. L., S. W. Tsang, M. L. Wong, C. H. Tse, N. W. Leung, F. K. Chan, and J. J. Sung. 2002. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am. J. Gastroenterol. 97 : 2629-2633.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Chan, H. L., M. L. Wong, A. Y. Hui, L. C. Hung, F. K. Chan, and J. J. Sung. 2003. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J. Clin. Microbiol. 41 : 1277-1279.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Chien, R. N., C. T. Yeh, S. L. Tsai, C. M. Chu, and Y. F. Liaw. 2003. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38 : 1267-1273.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Chu, C. J., M. Hussain, and A. S. Lok. 2002. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122 : 1756-1762.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Di Lello, F. A., Y. L. F. G. Pineiro, G. Munoz, and R. H. Campos. 2009. Diversity of hepatitis B and C viruses in Chile. J. Med. Virol. 81 : 1887-1894.
    OpenUrlCrossRefPubMed
  12. 12.↵
    European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50 : 227-242.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Fang, Z. L., C. A. Sabin, B. Q. Dong, S. C. Wei, Q. Y. Chen, K. X. Fang, J. Y. Yang, X. Y. Wang, and T. J. Harrison. 2009. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis. J. Hepatol. 50 : 273-280.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Fu, J., D. Xu, Z. Liu, M. Shi, P. Zhao, B. Fu, Z. Zhang, H. Yang, H. Zhang, C. Zhou, J. Yao, L. Jin, H. Wang, Y. Yang, Y. X. Fu, and F. S. Wang. 2007. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132 : 2328-2339.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Hsieh, T. H., T. C. Tseng, C. J. Liu, M. Y. Lai, P. J. Chen, H. L. Hsieh, D. S. Chen, and J. H. Kao. 2009. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir. Ther. 14 : 1157-1163.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Inoue, J., Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, Y. Yamagiwa, M. Shiina, Y. Kondo, E. Kakazu, K. Tamai, N. Obara, T. Iwasaki, and T. Shimosegawa. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J. Viral Hepat., in press.
  17. 17.↵
    Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124 : 327-334.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 : 554-559.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Lee, Y. S., Y. H. Chung, J. A. Kim, S. E. Kim, J. W. Shin, K. M. Kim, Y. S. Lim, N. H. Park, H. C. Lee, and D. J. Suh. 2009. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int. 29 : 552-556.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Liu, Y., C. M. Wang, J. Cheng, Z. L. Liang, Y. W. Zhong, X. Q. Ren, Z. H. Xu, F. Zoulim, and D. P. Xu. 2009. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin. Med. J. 122 : 1585-1586.
    OpenUrlPubMed
  21. 21.↵
    Liu, Y., Y. Zhong, Z. Zou, Z. Xu, B. Li, X. Ren, S. Bai, L. Wang, X. Li, J. Dai, Y. Wang, P. Mao, and D. Xu. 2010. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J. Clin. Virol. 47 : 243-247.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Lusida, M. I., V. E. Nugrahaputra, Soetjipto, R. Handajani, M. Nagano-Fujii, M. Sasayama, T. Utsumi, and H. Hotta. 2008. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J. Clin. Microbiol. 46 : 2160-2166.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Rehermann, B., and M. Nascimbeni. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 : 215-229.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Ren, X., Z. Xu, Y. Liu, X. Li, S. Bai, N. Ding, Y. Zhong, L. Wang, P. Mao, F. Zoulim, and D. Xu. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J. Viral Hepat., in press.
  25. 25.↵
    Sugauchi, F., E. Orito, T. Ichida, H. Kato, H. Sakugawa, S. Kakumu, T. Ishida, A. Chutaputti, C. L. Lai, R. G. Gish, R. Ueda, Y. Miyakawa, and M. Mizokami. 2003. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124 : 925-932.
    OpenUrlCrossRefPubMedWeb of Science
  26. 25a.↵
    Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software, version 4.0. Mol. Biol. Evol. 24 : 1596-1599.
    OpenUrlCrossRefPubMedWeb of Science
  27. 26.↵
    Tenney, D. J., S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer, L. Discotto, M. Plym, K. Pokornowski, C. F. Yu, P. Angus, A. Ayres, A. Bartholomeusz, W. Sievert, G. Thompson, N. Warner, S. Locarnini, and R. J. Colonno. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48 : 3498-3507.
    OpenUrlAbstract/FREE Full Text
  28. 27.↵
    Tenney, D. J., R. E. Rose, C. J. Baldick, S. M. Levine, K. A. Pokornowski, A. W. Walsh, J. Fang, C. F. Yu, S. Zhang, C. E. Mazzucco, B. Eggers, M. Hsu, M. J. Plym, P. Poundstone, J. Yang, and R. J. Colonno. 2007. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51 : 902-911.
    OpenUrlAbstract/FREE Full Text
  29. 28.↵
    Thakur, V., S. K. Sarin, S. Rehman, R. C. Guptan, S. N. Kazim, and S. Kumar. 2005. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J. Gastroenterol. 24 : 12-15.
    OpenUrlPubMed
  30. 29.↵
    Tseng, T. C., C. J. Liu, P. J. Chen, M. Y. Lai, C. L. Lin, J. H. Kao, and D. S. Chen. 2007. Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. Liver Int. 27 : 983-988.
    OpenUrlCrossRefPubMed
  31. 30.↵
    Wang, H. Y., D. Li, W. Liu, X. Jin, B. Du, Y. P. Li, H. X. Gu, and S. Y. Zhang. 2010. Hepatitis B virus subgenotype C2 is the most prevalent subgenotype in northeast China. Clin. Microbiol. Infect. 16 : 477-481.
    OpenUrlCrossRefPubMed
  32. 31.↵
    Wang, Z., J. Hou, G. Zeng, S. Wen, Y. Tanaka, J. Cheng, F. Kurbanov, L. Wang, J. Jiang, N. V. Naoumov, M. Mizokami, and Y. Qi. 2007. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. J. Viral Hepat. 14 : 426-434.
    OpenUrlCrossRefPubMedWeb of Science
  33. 32.↵
    Wang, Z., Y. Huang, S. Wen, B. Zhou, and J. Hou. 2007. Hepatitis B virus genotypes and subgenotypes in China. Hepatol. Res. 37 : S36-S41.
    OpenUrlCrossRefPubMed
  34. 33.↵
    Wang, Z., Y. Tanaka, Y. Huang, F. Kurbanov, J. Chen, G. Zeng, B. Zhou, M. Mizokami, and J. Hou. 2007. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J. Clin. Microbiol. 45 : 1491-1496.
    OpenUrlAbstract/FREE Full Text
  35. 34.↵
    Xu, D., J. Fu, L. Jin, H. Zhang, C. Zhou, Z. Zou, J. M. Zhao, B. Zhang, M. Shi, X. Ding, Z. Tang, Y. X. Fu, and F. S. Wang. 2006. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177 : 739-747.
    OpenUrlAbstract/FREE Full Text
  36. 35.↵
    Xu, D., Z. Zhang, F. Chu, Y. Li, L. Jin, L. Zhang, G. F. Gao, and F. S. Wang. 2004. Genetic variation of SARS coronavirus in Beijing Hospital. Emerg. Infect. Dis. 10 : 789-794.
    OpenUrlCrossRefPubMed
  37. 36.↵
    Xu, D., Z. Zhang, L. Jin, F. Chu, Y. Mao, H. Wang, M. Liu, M. Wang, L. Zhang, G. F. Gao, and F. S. Wang. 2005. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur. J. Clin. Microbiol. Infect. Dis. 24 : 165-171.
    OpenUrlCrossRefPubMed
  38. 37.↵
    Xu, D., Z. Zhang, and F. S. Wang. 2004. SARS-associated coronavirus quasispecies in individual patients. N. Engl. J. Med. 350 : 1366-1367.
    OpenUrlCrossRefPubMed
  39. 38.↵
    Xu, Z., Y. Liu, T. Xu, L. Chen, L. Si, Y. Wang, X. Ren, Y. Zhong, J. Zhao, and D. Xu. 2010. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J. Clin. Virol. 48 : 270-274.
    OpenUrlCrossRefPubMed
  40. 39.↵
    Yin, J., H. Zhang, C. Li, C. Gao, Y. He, Y. Zhai, P. Zhang, L. Xu, X. Tan, J. Chen, S. Cheng, S. Schaefer, and G. Cao. 2008. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 29 : 1685-1691.
    OpenUrlCrossRefPubMedWeb of Science
  41. 40.↵
    Yuan, J., B. Zhou, Y. Tanaka, F. Kurbanov, E. Orito, Z. Gong, L. Xu, J. Lu, X. Jiang, W. Lai, and M. Mizokami. 2007. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. J. Clin. Virol. 39 : 87-93.
    OpenUrlCrossRefPubMedWeb of Science
  42. 41.↵
    Zhang, H. W., J. H. Yin, Y. T. Li, C. Z. Li, H. Ren, C. Y. Gu, H. Y. Wu, X. S. Liang, P. Zhang, J. F. Zhao, X. J. Tan, W. Lu, S. Schaefer, and G. W. Cao. 2008. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 57 : 1713-1720.
    OpenUrlAbstract/FREE Full Text
  43. 42.↵
    Zhu, L., C. H. Tse, V. W. Wong, A. M. Chim, K. S. Leung, and H. L. Chan. 2008. A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. J. Viral Hepat. 15 : 449-458.
    OpenUrlCrossRefPubMed
  44. 43.↵
    Zollner, B., J. Petersen, E. Puchhammer-Stockl, J. Kletzmayr, M. Sterneck, L. Fischer, M. Schroter, R. Laufs, and H. H. Feucht. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39 : 42-50.
    OpenUrlCrossRefPubMedWeb of Science
  45. 44.↵
    Zou, Z., D. Xu, B. Li, S. Xin, Z. Zhang, L. Huang, J. Fu, Y. Yang, L. Jin, J. M. Zhao, M. Shi, G. Zhou, Y. Sun, and F. S. Wang. 2009. Compartmentalization and its implication for peripheral immunologically-competent cells to the liver in patients with HBV-related acute-on-chronic liver failure. Hepatol. Res. 39 : 1198-1207.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients
Xiaodong Li, Lin Wang, Yanwei Zhong, Vincent Wai-Sun Wong, Zhihui Xu, Yan Liu, Qinghong Li, Shaojie Xin, Jingmin Zhao, Dongping Xu
Journal of Clinical Microbiology Nov 2010, 48 (12) 4363-4369; DOI: 10.1128/JCM.01518-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hepatitis B Virus (HBV) Subgenotypes C2 and B2 Differ in Lamivudine- and Adefovir-Resistance-Associated Mutational Patterns in HBV-Infected Chinese Patients
Xiaodong Li, Lin Wang, Yanwei Zhong, Vincent Wai-Sun Wong, Zhihui Xu, Yan Liu, Qinghong Li, Shaojie Xin, Jingmin Zhao, Dongping Xu
Journal of Clinical Microbiology Nov 2010, 48 (12) 4363-4369; DOI: 10.1128/JCM.01518-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Adenine
Antiviral Agents
Drug Resistance, Viral
hepatitis B virus
Lamivudine
Mutation, Missense
Organophosphonates

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X